Avoiding the 30-Day Readmission Trap in Heart Failure Care

Heart failure readmissions are rarely caused by a single clinical mistake. A patient may leave hospital with improved breathlessness, then return within weeks because medicines are confusing, weight gain goes unnoticed, transport fails, or a follow-up appointment is too late. The 30-day window therefore tests the whole care system, not just the discharge summary.

Lessons discussed at Hospital Medicine 2017 (HM17) remain relevant for Australian hospitals. The HM17 conference archive highlights the event’s focus on hospital medicine, patient safety, practical innovation and coordinated care. For Australian clinicians, those themes connect directly with Medicare-funded general practice, rural distance, Aboriginal health services and the need to make every transition workable for patients and carers.

Why Thirty Days Matters

A readmission within 30 days can reflect relapse, an avoidable medication problem, an unresolved social issue or an appropriate response to worsening disease. Treating every return as a failure creates the wrong incentives. The useful question is whether the patient’s risks were identified, communicated and actively managed after discharge.

Heart failure is particularly vulnerable to this gap. Fluid status can change quickly, renal function may deteriorate after diuretic adjustments, and symptoms can be mistaken for a chest infection or normal ageing. Patients often remember “take the new tablet” more easily than the reason for daily weights, the action threshold for swelling or the number to call when breathlessness increases.

Australian hospital teams also work across fragmented settings. A patient discharged in western Sydney may see a busy GP within a week, while someone in regional Queensland may face a long drive, limited cardiology access and unreliable internet. A person in the Northern Territory may rely on an Aboriginal Community Controlled Health Service or an outreach team. A safe plan must account for those realities rather than assume urban specialist access.

Begin Before the Discharge Date

Readmission prevention starts with clinical stabilisation and a clear explanation of what happens next. Medication reconciliation should compare the pre-admission list, inpatient orders and intended discharge regimen. The team should identify stopped medicines, changed doses, high-risk combinations and the practical cost of filling prescriptions under the Pharmaceutical Benefits Scheme.

The discharge conversation needs to be demonstrable, not merely documented. Ask the patient or carer to explain the plan in their own words: which medicines are taken in the morning, how weight is tracked, what symptoms matter and whom to contact. Written instructions should use plain English and large, readable formatting. If English is not the person’s first language, a qualified interpreter is safer than relying on a relative.

A useful plan includes a target or “dry” weight where appropriate, a symptom action plan and clear escalation pathways. It should state when to call the GP, heart failure nurse, hospital service or emergency number. For people using My Health Record, discharge information can support continuity, but electronic uploading does not replace direct communication with the GP and community team.

Make Follow-Up Specific And Fast

“Follow up with your doctor” is too vague to prevent deterioration. A stronger transition plan names the service, expected timing, responsible clinician and information to be shared. Many patients benefit from GP review within a week, with earlier contact for significant medication changes, renal impairment, persistent congestion or limited self-management capacity.

The first review should be purposeful. It may include symptoms, weight trend, blood pressure, pulse, renal function, electrolytes, medicine access and adherence. A heart failure nurse can reinforce education and identify deterioration before an ambulance is required. Pharmacists can check dose timing, duplications, adverse effects and whether the patient can physically open, organise and collect the medicines.

Telehealth can help, especially for people in rural and remote Australia, but it should be matched to digital access and preference. A phone call may be more reliable than a video appointment for an older person with limited data. Local community nurses, residential aged-care staff, carers and Aboriginal health workers can provide observations that a hospital record will never capture.

Leadership matters because delayed discharge and poor bed flow can encourage rushed transitions. HM17’s patient flow leadership primer is relevant here: efficient flow should support safe decisions, not turn discharge into a race for bed availability.

Treat Medicines And Self-Management As Clinical Care

Guideline-directed therapy can improve outcomes, yet the regimen may be difficult to start and maintain. Patients may leave with a beta blocker, renin-angiotensin system therapy, mineralocorticoid receptor antagonist, diuretic or newer therapy such as an SGLT2 inhibitor. Each has potential benefits and monitoring requirements. The discharge plan should explain why the medicine matters, what side effects to watch for and when blood tests are needed.

Medication adherence is often shaped by practical barriers. A patient may ration tablets because of cost, have poor vision, struggle with blister packs or stop treatment after dizziness. Ask directly about affordability and daily routines. Pharmacists, Home Medicines Review services and dose administration aids may help, though they must be coordinated with prescribers so that a packaging solution does not conceal a necessary dose change.

Fluid and sodium advice should be individualised. Broad warnings can lead some people to drink too little, while others receive inconsistent messages from different clinicians. The plan should match the patient’s kidney function, congestion status, climate, work and usual diet. In Australia, heat exposure and long travel can complicate fluid management, particularly for people living remotely or working outdoors.

Carers need inclusion and consent. They may notice increasing fatigue, confusion, ankle swelling or missed medicines before the patient does. Education should respect health literacy, culture and autonomy. Where capacity is uncertain, clinicians should assess decision-making ability carefully rather than assuming that an older age, disability or disagreement proves incapacity. HM17’s discussion of capacity assessment workshops offers a useful ethical lens for these conversations.

Use Data To Find The Real Causes

Hospitals should examine their own readmission patterns rather than copy a generic bundle. Useful data include the timing of return, primary diagnosis, emergency department presentations that did not lead to admission, medication changes, missed appointments, renal complications and documented contact after discharge. Reviewing cases with clinicians, patients and carers can expose failures that administrative data cannot.

Risk scores can support prioritisation, but they should not determine care in isolation. A patient with modest physiological risk may be highly vulnerable because of homelessness, cognitive impairment, family strain, language barriers or a long distance from care. Conversely, a patient with complex disease may manage well with strong family support and reliable specialist follow-up.

A small number of operational measures can keep improvement practical. Teams might track the proportion of patients leaving with a reconciled medicine list, documented teach-back, a booked follow-up appointment, a communicated weight plan and completed post-discharge contact. Balancing measures are important too: monitor emergency workload, staff time, patient experience and unintended delays in discharge.

Hospitals can test changes through short improvement cycles. One ward may trial pharmacist review before midday; another may create a direct nurse-to-GP handover; a rural service may coordinate pathology with an existing community visit. Results should be reviewed by clinicians and consumers, with adjustments based on what actually works.

Build A Shared Transition System

A dependable heart failure pathway assigns ownership. The inpatient team confirms readiness and communicates the plan. The GP or community clinician reviews the patient after discharge. The specialist or heart failure service provides escalation advice. Nurses, pharmacists, carers and Aboriginal health professionals contribute according to the patient’s circumstances. If everyone is “involved” but no one is responsible, important tasks can fall between services.

The handover should contain the diagnosis, ejection fraction when known, recent clinical course, medicine changes, monitoring requirements, follow-up arrangements, pending tests, warning signs and a named contact. Sending a letter eventually is not equivalent to a warm handover. A phone call may be appropriate for a high-risk patient, especially when the receiving clinician needs to clarify treatment or access barriers.

Hospitals should also plan for deterioration without making the emergency department the only safety net. Some services offer rapid-access heart failure clinics, ambulatory diuretic pathways or nurse-led review. These models require governance, clear eligibility and timely medical support, but they can provide an alternative to admission for selected patients.

The most effective programmes are designed with consumers. Patients can identify confusing instructions, inconvenient appointment times and language that sounds clear to clinicians but not to families. In Australia, co-design should include people from culturally diverse communities, Aboriginal and Torres Strait Islander communities, regional areas and residential aged care.

Practical Priorities For Safer Transitions

A hospital can focus its effort on a few reliable actions rather than launch a large bundle that no team can sustain.

• Reconcile medicines with the patient and carer, then use teach-back to confirm understanding.
• Book follow-up before discharge and match the timing to clinical risk, distance and access.
• Provide a written symptom, weight and escalation plan with a real contact pathway.
• Share a concise handover with the GP, pharmacist, community nurse and relevant specialist service.
• Review every early return to identify system causes, patient priorities and missed opportunities.

The central lesson from HM17 is that preventing avoidable heart failure readmission is a systems task expressed through individual care. Stabilising the patient matters, but so do clear instructions, accessible medicines, rapid review, reliable communication and respect for the person’s home context.

For Australian practice, success means a plan that survives the trip home, the next weekend, the distance to pathology and the realities of Medicare-funded care. The point to remember is simple: a discharge is safe when the next team, the patient and the carer all know what will happen next and how to respond when the clinical picture changes.